Susquehanna International Group, LLP Regeneron Pharmaceuticals, Inc. Call Options Transaction History

Susquehanna International Group, LLP

$560 Billion
Q3 2024

Call Options

29 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$1024.09 - $1201.76 $72.2 Million - $84.7 Million	70,500 Added 30.83%	299,200 $315 Million
Q2 2024 Aug 15, 2024	SELL	$883.2 - $1071.19 $15.7 Million - $19.1 Million	-17,800 Reduced 7.22%	228,700 $240 Million
Q1 2024 May 07, 2024	SELL	$902.69 - $993.35 $195 Million - $215 Million	-216,000 Reduced 46.7%	246,500 $237 Million
Q4 2023 Feb 14, 2024	BUY	$775.18 - $881.7 $14.7 Million - $16.8 Million	19,000 Added 4.28%	462,500 $406 Million
Q3 2023 Nov 14, 2023	SELL	$692.45 - $844.37 $107 Million - $131 Million	-154,800 Reduced 25.87%	443,500 $365 Million
Q2 2023 Aug 11, 2023	SELL	$700.03 - $830.35 $176 Million - $208 Million	-251,000 Reduced 29.55%	598,300 $430 Million
Q1 2023 May 16, 2023	BUY	$680.49 - $826.97 $109 Million - $132 Million	159,600 Added 23.14%	849,300 $698 Million
Q4 2022 Feb 14, 2023	BUY	$705.89 - $766.39 $27.5 Million - $29.8 Million	38,900 Added 5.98%	689,700 $498 Million
Q3 2022 Nov 14, 2022	BUY	$573.97 - $724.32 $153 Million - $193 Million	266,300 Added 69.26%	650,800 $448 Million
Q2 2022 Aug 15, 2022	BUY	$548.35 - $738.84 $46.4 Million - $62.6 Million	84,700 Added 28.25%	384,500 $227 Million
Q1 2022 May 16, 2022	SELL	$595.12 - $698.43 $144 Million - $169 Million	-242,100 Reduced 44.68%	299,800 $209 Million
Q4 2021 Feb 14, 2022	SELL	$543.48 - $670.97 $170 Million - $210 Million	-313,100 Reduced 36.62%	541,900 $342 Million
Q3 2021 Nov 15, 2021	BUY	$574.03 - $680.96 $55.8 Million - $66.2 Million	97,200 Added 12.83%	855,000 $517 Million
Q2 2021 Aug 11, 2021	SELL	$472.8 - $558.54 $117 Million - $138 Million	-247,000 Reduced 24.58%	757,800 $423 Million
Q1 2021 May 17, 2021	BUY	$446.73 - $548.2 $136 Million - $166 Million	303,600 Added 43.3%	1,004,800 $475 Million
Q4 2020 Feb 16, 2021	BUY	$478.3 - $607.98 $84 Million - $107 Million	175,600 Added 33.41%	701,200 $339 Million
Q3 2020 Nov 16, 2020	SELL	$544.75 - $658.21 $89.3 Million - $108 Million	-164,000 Reduced 23.78%	525,600 $294 Million
Q2 2020 Aug 14, 2020	SELL	$493.32 - $643.92 $118 Million - $154 Million	-239,900 Reduced 25.81%	689,600 $430 Million
Q1 2020 May 15, 2020	BUY	$336.18 - $494.43 $83.7 Million - $123 Million	249,100 Added 36.61%	929,500 $454 Million
Q4 2019 Feb 14, 2020	BUY	$274.13 - $376.51 $73.7 Million - $101 Million	268,800 Added 65.31%	680,400 $255 Million
Q3 2019 Nov 14, 2019	SELL	$273.46 - $318.39 $820,379 - $955,170	-3,000 Reduced 0.72%	411,600 $114 Million
Q2 2019 Aug 14, 2019	BUY	$299.6 - $414.82 $10.6 Million - $14.7 Million	35,400 Added 9.34%	414,600 $130 Million
Q1 2019 May 15, 2019	SELL	$372.08 - $439.57 $134 Million - $158 Million	-360,100 Reduced 48.71%	379,200 $156 Million
Q4 2018 Feb 14, 2019	SELL	$335.82 - $403.04 $30.1 Million - $36.1 Million	-89,500 Reduced 10.8%	739,300 $276 Million
Q3 2018 Nov 14, 2018	BUY	$351.14 - $408.51 $91.5 Million - $106 Million	260,600 Added 45.86%	828,800 $335 Million
Q2 2018 Aug 14, 2018	SELL	$284.6 - $344.99 $14.1 Million - $17.1 Million	-49,700 Reduced 8.04%	568,200 $196 Million
Q1 2018 May 15, 2018	SELL	$315.82 - $393.78 $216 Million - $269 Million	-684,300 Reduced 52.55%	617,900 $213 Million
Q4 2017 Feb 14, 2018	BUY	$358.63 - $469.95 $118 Million - $155 Million	329,500 Added 33.87%	1,302,200 $490 Million
Q3 2017 Nov 14, 2017	BUY	$431.38 - $504.0 $420 Million - $490 Million	972,700	972,700 $435 Million

Others Institutions Holding REGN

# of Institutions

1,534

Shares Held

83.8M

Call Options Held

1.22M

Put Options Held

1.51M

View Full List

About REGENERON PHARMACEUTICALS, INC.

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $82.9B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

More about REGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account